top of page
Antibody screening photo 1.png

Novel screening of monoclonal antibody-based therapeutics (mAbs) by LC-MS/MS

Introduce more specificity into your projects for greater sensitivity and better method performance.

Drastically decrease the lead time for bioanalysis with our novel LC-MS/MS workflow that can be applied to all human IgG-based therapeutics.

Icon of a clock with three speed lines extending from the left side, to depict the ability to initiate projects quickly
Initiate projects quickly
A simple blue line drawing of two test tubes containing liquid and bubbles, tilted towards each other
Eliminate upfront reagents
A blue icon of stacked server units with circular connectors depicted on each unit to show the ability to do work in parallel
Conduct parallel work

Get rapid and sensitive quantitation of human mAbs in serum from sera of nonclinical species

Our hybrid LC-MS/MS assay permits rapid and sensitive quantitation of human mAbs in serum from sera of nonclinical species. In addition, the broad specificity of the antiserum for IgG subclasses allows this assay to function in a plug-and-play manner with minimal optimization for efficient support of nonclinical PK of different monoclonal-based therapeutics and ADCs across nonclinical species.

A Veloxity Labs scientist using a pipette to transfer liquid into a test tube in a laboratory.
Robotic pipettes dispense liquid samples into a multi-well plate in a laboratory.

What's next?

What's next in the development pipeline for this novel screening method? We plan to expand scope to include additional mAbs and biotherapeutics containing human light chains. Also, check in with us as we investigate additional signature peptides by LC-MS/ MS corresponding to conserved sequences of IgG2, IgG3.

Brought to you by Veloxity Labs and
B2S Life Sciences

This innovative workflow was proudly developed in partnership between Veloxity Labs, LLC and B2S Life Sciences, LLC.

 

A special thank you to the following individuals for their significant contributions to this workflow:

  • B2S Life Sciences: Adam S. Kinne, Elijah S. Parmer, Sanofar J. Abdeen, Ronald R. Bowsher

  • Veloxity Labs: Mitch Johnson, Shane Needham, Colt Cookson

The B2S Life Sciences logo in large blue and orange letters, followed by the tagline "enabling excellence in biotherapeutics"

Contact us today.

Let's talk about how we can help introduce more specificity into your projects for greater sensitivity and better method performance.

bottom of page